A Phase 4 interventional study of rituximab [MabThera/Rituxan] in Non-Hodgkin's Lymphoma, sponsored by Hoffmann-La Roche. Completed at 178 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-08-14.
Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 178 studies testing rituximab in Lymphoma, Non-Hodgkin — 5 open to participants now, 11 under way, 2 of them phase 3. Rituximab · Lymphoma, Non-Hodgkin.
Among the 178 studies testing rituximab in Lymphoma, Non-Hodgkin, this one is the 9th largest by enrollment of the 171 interventional ones that give a count, is one of 17 that started in 2006, is one of 5 in phase 4, and was the 74th registered.
2,288 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.
Browse Lymphoma, Non-Hodgkin studies →5 of the 178 studies testing rituximab in Lymphoma, Non-Hodgkin are open now, in 2 countries. Recruiting first, the newest first:
Paolo Caimi, MD · Sites in United States
Ages 18+
Reid Merryman, MD · Sites in United States
Ages 18+
University of Cologne · Sites in Germany
Ages 18–99
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
M.D. Anderson Cancer Center · Sites in United States
Ages 15–80
By country, each count listing its studies:
Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 242 Lymphoma, Non-Hodgkin studies recruiting now, 142 (59%) set no upper age limit and 77 (32%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
178 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 43 · Phase 2 112 · Phase 3 30 · Phase 4 5
First in 1995; this study’s year is marked. 17 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 545 is above the median of 40 across 1,883 interventional studies indexed under Lymphoma, Non-Hodgkin.
Median enrollment 38 across the 171 interventional studies. Of the 152 that completed or were terminated, 80 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 178 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
54 studies in Lymphoma, Non-Hodgkin by Hoffmann-La Roche: 1 open now, 6 under way, 1 of them phase 3. Of 47 finished, 22 (47%) have results posted.
Among the 54 studies in Lymphoma, Non-Hodgkin by Hoffmann-La Roche, this one is the 7th largest by enrollment of the 49 interventional ones that give a count, is one of 3 that started in 2006, is one of 2 in phase 4, and was the 5th registered.
Hoffmann-La Roche’s Lymphoma, Non-Hodgkin studies by the year they started, since 1997.
4 of the studies testing rituximab in Lymphoma, Non-Hodgkin that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05578976Phase 3GenmabA Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) | 2027-06 |
| NCT05583071University of CologneMethotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL | 2027-02 |
| NCT01829958Memorial Sloan Kettering Cancer CenterComprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy | 2027-04 |
| NCT02727803M.D. Anderson Cancer CenterPersonalized NK Cell Therapy in CBT | 2027-05-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 178 studies testing rituximab in Lymphoma, Non-Hodgkin, from their registry updates:
Among Hoffmann-La Roche’s 54 in Lymphoma, Non-Hodgkin:
This tab as a report to print or save as PDF → With an account.
This single arm study will evaluate the safety and efficacy of MabThera maintenance therapy following a MabThera-containing induction regimen in first line or relapsed patients with follicular non-Hodgkin's lymphoma. All patients will receive MabThera 375mg/m2 body surface area, as an intravenous infusion, every 8 weeks. The anticipated time on study treatment is 1-2 years, and the target sample size is 500+ individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: rituximab [MabThera/Rituxan]
Drug page: Rituximab
375mg/m2 iv every 8 weeks
Percentage of Participants With an Adverse Event (AE) - Overall Summary
Data presented include percentage of participants with any AE, any infusion-related AE, any serious adverse event (SAE), any infusion-related SAE (counted separately from SAEs), death, and participants with toxicity as the primary cause for treatment discontinuation.
Time frame: 24 months
Progression-Free Survival - Percentage of Participants With an Event
PFS was measured from the day of first rituximab maintenance infusion until the date of first documented disease progression or death by any cause. Participants who experienced none of these events at the time of analysis (clinical cutoff) and participants who were lost to follow-up were censored at their last clinical assessment date.
Time frame: Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose
Progression-Free Survival - Time to Event
PFS was measured from the day of first rituximab maintenance infusion until the date of first documented disease progression or death by any cause. Participants who experienced none of these events at the time of analysis (clinical cutoff) and participants who were lost to follow-up were censored at their last clinical assessment date.
Time frame: Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose
Event-Free Survival (EFS) - Percentage of Participants With an Event
The percentage of participants who experienced PD or death or required a next or new lymphoma treatment over a study period of 2 years with 1 year of follow-up. EFS was measured from the day of first rituximab maintenance infusion until the date of first documented disease progression, death by any cause, or the institution of new anti-lymphoma treatment. Participants who experienced none of these events at the end of the study and participants who were lost to follow-up were censored at their last clinical assessment date.
Time frame: Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose
Event-Free Survival (EFS) - Time to Event
EFS was measured from the day of first rituximab maintenance infusion until the date of first documented disease progression, death by any cause, or the institution of new anti-lymphoma treatment. Participants who experienced none of these events at the end of the study and participants who were lost to follow-up were censored at their last clinical assessment date.
Time frame: Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose
Overall Survival (OS) - Percentage of Participants With an Event
As a measure of overall survival (OS), the percentage of participants who died over the study period of 2 years with 1 year of follow-up. OS was determined from the day of first rituximab maintenance infusion until the date of death irrespective of cause. Participants who had not died at the time of end of the whole study and participants who were lost to follow up were censored at the date of the last contact.
Time frame: Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose
Overall Survival (OS) - Time to Event
OS was determined from the day of first rituximab maintenance infusion until the date of death irrespective of cause. Participants who had not died at the time of end of the whole study and participants who were lost to follow up were censored at the date of the last contact.
Time frame: Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose
Time to Next Lymphoma Treatment (NLT) - Percentage of Participants With an Event
As a measure of time to NLT (TNLT), the percentage of participants with new lymphoma treatment over a study period of 2 years with 1 year of follow-up. TNLT was measured from the date of first rituximab maintenance infusion to the date of first documented intake of any new anti-lymphoma treatment (chemotherapy, radiotherapy, immunotherapy, etc). Participants who did not have documentation that an NLT had started and participants who were lost to follow up were censored at their last visit where the assessment for start of any new lymphoma medication was actually made.
Time frame: Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose
Time to NLT - Time to Event
TNLT was measured from the date of first rituximab maintenance infusion to the date of first documented intake of any new anti-lymphoma treatment (chemotherapy, radiotherapy, immunotherapy, etc). Participants who did not have documentation that an NLT had started and participants who were lost to follow up were censored at their last visit where the assessment for start of any new lymphoma medication was actually made.
Time frame: Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose
Percentage of Participants With Response by Best Response to Study Treatment
Percentage of participants with complete response (CR), unconfirmed CR (CRu), no change, or progressive disease (PD). For each participant, the last response to induction therapy immediately prior to study entry was compared to the best response observed during rituximab maintenance therapy. Where possible, assessment of response was based on the International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphoma (NHL).
Time frame: Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose
Percentage of Participants With PR Who Converted to CRu
Percentage of participants with PR or CR(u) conversion while on rituximab maintenance therapy over a study period of 2 years with 1 year of follow-up. For each participant, the last response to induction therapy immediately prior to study entry was compared to the best response observed during rituximab maintenance therapy. Assessment and definition of response was based on the International Workshop to Standardize Response Criteria for NHL.
Time frame: Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose
| Milestone | Rituximab 375 Milligrams Per Square Meter (mg/m^2) |
|---|---|
| Started | 545 |
| Completed | 407 |
| Not completed | 138 |
| Withdrew: Disease progression | 58 |
| Withdrew: Withdrawal by subject | 11 |
| Withdrew: Adverse event | 16 |
| Withdrew: Death | 5 |
| Withdrew: Other | 48 |
Data presented include percentage of participants with any AE, any infusion-related AE, any serious adverse event (SAE), any infusion-related SAE (counted separately from SAEs), death, and participants with toxicity as the primary cause for treatment discontinuation.
| percentage of participants | Rituximab 375 mg/m^2 |
|---|---|
| Any AE | 67.4 |
| Any infusion-related AE | 5.8 |
| Any non-infusion related SAE | 20.2 |
| Any infusion-related SAE | 0.2 |
| Deaths | 7.5 |
| Toxicity as primary cause for discontinuation | 3.0 |
PFS was measured from the day of first rituximab maintenance infusion until the date of first documented disease progression or death by any cause. Participants who experienced none of these events at the time of analysis (clinical cutoff) and participants who were lost to follow-up were censored at their last clinical assessment date.
| percentage of participants | Rituximab 375 mg/m^2 |
|---|---|
| Progression-Free Survival - Percentage of Participants With an Event | 24.0 |
PFS was measured from the day of first rituximab maintenance infusion until the date of first documented disease progression or death by any cause. Participants who experienced none of these events at the time of analysis (clinical cutoff) and participants who were lost to follow-up were censored at their last clinical assessment date.
| months | Rituximab 375 mg/m^2 |
|---|---|
| Progression-Free Survival - Time to Event | NA (NA to NA) |
The percentage of participants who experienced PD or death or required a next or new lymphoma treatment over a study period of 2 years with 1 year of follow-up. EFS was measured from the day of first rituximab maintenance infusion until the date of first documented disease progression, death by any cause, or the institution of new anti-lymphoma treatment. Participants who experienced none of these events at the end of the study and participants who were lost to follow-up were censored at their last clinical assessment date.
| percentage of participants | Rituximab 375 mg/m^2 |
|---|---|
| Event-Free Survival (EFS) - Percentage of Participants With an Event | 24.4 |
EFS was measured from the day of first rituximab maintenance infusion until the date of first documented disease progression, death by any cause, or the institution of new anti-lymphoma treatment. Participants who experienced none of these events at the end of the study and participants who were lost to follow-up were censored at their last clinical assessment date.
| months | Rituximab 375 mg/m^2 |
|---|---|
| Event-Free Survival (EFS) - Time to Event | NA (NA to NA) |
As a measure of overall survival (OS), the percentage of participants who died over the study period of 2 years with 1 year of follow-up. OS was determined from the day of first rituximab maintenance infusion until the date of death irrespective of cause. Participants who had not died at the time of end of the whole study and participants who were lost to follow up were censored at the date of the last contact.
| percentage of participants | Rituximab 375 mg/m^2 |
|---|---|
| Overall Survival (OS) - Percentage of Participants With an Event | 7.3 |
OS was determined from the day of first rituximab maintenance infusion until the date of death irrespective of cause. Participants who had not died at the time of end of the whole study and participants who were lost to follow up were censored at the date of the last contact.
| percentage of participants | Rituximab 375 mg/m^2 |
|---|---|
| Overall Survival (OS) - Time to Event | NA (NA to NA) |
As a measure of time to NLT (TNLT), the percentage of participants with new lymphoma treatment over a study period of 2 years with 1 year of follow-up. TNLT was measured from the date of first rituximab maintenance infusion to the date of first documented intake of any new anti-lymphoma treatment (chemotherapy, radiotherapy, immunotherapy, etc). Participants who did not have documentation that an NLT had started and participants who were lost to follow up were censored at their last visit where the assessment for start of any new lymphoma medication was actually made.
| percentage of participants | Rituximab 375 mg/m^2 |
|---|---|
| Time to Next Lymphoma Treatment (NLT) - Percentage of Participants With an Event | 17.4 |
TNLT was measured from the date of first rituximab maintenance infusion to the date of first documented intake of any new anti-lymphoma treatment (chemotherapy, radiotherapy, immunotherapy, etc). Participants who did not have documentation that an NLT had started and participants who were lost to follow up were censored at their last visit where the assessment for start of any new lymphoma medication was actually made.
| months | Rituximab 375 mg/m^2 |
|---|---|
| Time to NLT - Time to Event | NA (NA to NA) |
Percentage of participants with complete response (CR), unconfirmed CR (CRu), no change, or progressive disease (PD). For each participant, the last response to induction therapy immediately prior to study entry was compared to the best response observed during rituximab maintenance therapy. Where possible, assessment of response was based on the International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphoma (NHL).
| percentage of participants | Rituximab 375 mg/m^2 |
|---|---|
| CR/CRu | 2.1 |
| No change | 87.5 |
| PD | 10.5 |
Percentage of participants with PR or CR(u) conversion while on rituximab maintenance therapy over a study period of 2 years with 1 year of follow-up. For each participant, the last response to induction therapy immediately prior to study entry was compared to the best response observed during rituximab maintenance therapy. Assessment and definition of response was based on the International Workshop to Standardize Response Criteria for NHL.
| percentage of participants | Rituximab 375 mg/m^2 |
|---|---|
| Percentage of Participants With PR Who Converted to CRu | 6.2 (3.0 to 11.1) |
Collected over AEs were collected at up through 12 months after last dose (1 year follow-up).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rituximab 375 mg/m^2 | — | 109/534 (20.4%) | 207/534 (38.8%) |
| Event | Rituximab 375 mg/m^2 |
|---|---|
| PneumoniaInfections and infestations | 7/534 |
| PyrexiaGeneral disorders | 4/534 |
| NeutropeniaBlood and lymphatic system disorders | 4/534 |
| AppendicitisInfections and infestations | 3/534 |
| DiarrhoeaGastrointestinal disorders | 3/534 |
| Cerebral haemorrhageNervous system disorders | 3/534 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/534 |
| Febrile neutropeniaBlood and lymphatic system disorders | 3/534 |
| SinusitisInfections and infestations | 2/534 |
| Coronary artery diseaseCardiac disorders | 2/534 |
| Event | Rituximab 375 mg/m^2 |
|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 50/534 |
| FatigueGeneral disorders | 40/534 |
| NasopharyngitisInfections and infestations | 38/534 |
| Blood lactate dehydrogenase increasedInvestigations | 37/534 |
| Back painMusculoskeletal and connective tissue disorders | 35/534 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 34/534 |
| HypertensionVascular disorders | 32/534 |
| DiarrhoeaGastrointestinal disorders | 31/534 |
| HeadacheNervous system disorders | 31/534 |
| Neutrophil count decreasedInvestigations | 29/534 |
Intent-to-treat (ITT) population: all participants who completed a baseline visit and at least 1 further assessment.
| Age, Continuous(years) | Rituximab 375 mg/m^2 |
|---|---|
| Mean | 56.3 ± 11.47 |
| Sex: Female, Male(Participants) | Rituximab 375 mg/m^2 |
|---|---|
| Female | 313 |
| Male | 232 |
Showing the first 100 of 178 sites across 24 countries. Choose a country and city above to see the rest.
Ran from Sep 2006 to primary completion in May 2011, 56 months.
Results were first posted in Jun 2015, 4 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rituximab